CDK2 inhibition enhances CDK4/6 inhibitor antitumor activity in comprehensive breast cancer PDX model screen.
Saved in:
| Title: | CDK2 inhibition enhances CDK4/6 inhibitor antitumor activity in comprehensive breast cancer PDX model screen. |
|---|---|
| Authors: | House NC; Blueprint Medicines Corporation, Cambridge, MA, USA. NHouse@blueprintmedicines.com., Chen MM; Blueprint Medicines Corporation, Cambridge, MA, USA., Khazaei S; TRACTION - Translational Research to AdvanCe Therapeutics and Innovation in ONcology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Brown V; Blueprint Medicines Corporation, Cambridge, MA, USA., Ramsden P; Blueprint Medicines Corporation, Cambridge, MA, USA., Peng DH; TRACTION - Translational Research to AdvanCe Therapeutics and Innovation in ONcology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Moore S; Blueprint Medicines Corporation, Cambridge, MA, USA., Yuan L; Blueprint Medicines Corporation, Cambridge, MA, USA., Wu R; Blueprint Medicines Corporation, Cambridge, MA, USA., Wang F; TRACTION - Translational Research to AdvanCe Therapeutics and Innovation in ONcology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Luo L; Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Feng N; TRACTION - Translational Research to AdvanCe Therapeutics and Innovation in ONcology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Bristow CA; TRACTION - Translational Research to AdvanCe Therapeutics and Innovation in ONcology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Yap TA; Department of Investigational Cancer Therapeutics, Therapeutic Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Keyomarsi K; Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Marszalek JR; TRACTION - Translational Research to AdvanCe Therapeutics and Innovation in ONcology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ribich S; Blueprint Medicines Corporation, Cambridge, MA, USA., Rinne ML; Blueprint Medicines Corporation, Cambridge, MA, USA., Muthuswamy LB; Blueprint Medicines Corporation, Cambridge, MA, USA., Faia KL; Blueprint Medicines Corporation, Cambridge, MA, USA. |
| Source: | NPJ breast cancer [NPJ Breast Cancer] 2025 Dec 03; Vol. 11 (1), pp. 135. Date of Electronic Publication: 2025 Dec 03. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Breast Cancer Research Foundation Country of Publication: United States NLM ID: 101674891 Publication Model: Electronic Cited Medium: Print ISSN: 2374-4677 (Print) Linking ISSN: 23744677 NLM ISO Abbreviation: NPJ Breast Cancer Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2374-4677 |
|---|---|
| DOI: | 10.1038/s41523-025-00851-7 |
